MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
68.03
-1.41
-2.03%
After Hours: 68.11 +0.08 +0.12% 16:53 04/01 EDT
OPEN
69.98
PREV CLOSE
69.44
HIGH
70.00
LOW
67.64
VOLUME
6.21M
TURNOVER
--
52 WEEK HIGH
145.25
52 WEEK LOW
66.88
MARKET CAP
302.06B
P/E (TTM)
21.64
1D
5D
1M
3M
1Y
5Y
1D
Eli Lilly weight loss therapy added to Hims & Hers platform
Seeking Alpha · 3h ago
Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
TipRanks · 6h ago
Trump unlikely to specify any pharma tariffs in ‘Liberation Day’ announcement: Reuters
Seeking Alpha · 9h ago
Eli Lilly takes actions to stop compounders from making its weight loss med
Seeking Alpha · 11h ago
These 2 Mega-Cap Stocks Could Be Even Cheaper Buys Than Nvidia on the Dip
Barchart · 14h ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Seeking Alpha · 1d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 1d ago
PGIM Jennison Global Opportunities Fund Q4 2024 Commentary
Seeking Alpha · 1d ago
More
About NVO
More
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Recently
Symbol
Price
%Change
    RTX
  • 132.85
  • +0.29%

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.